Clinical trials: Breast Cancer Female
Breast Cancer
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane, letrozole, or anastrozole, may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00265759
- Testing
- anastrozole, exemestane, letrozole
- Where
- 3 sites in United States
- Volunteers
- 622 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Letrozole in Preventing Breast Cancer in Postmenopausal Women
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Letrozole may be effective in preventing the development or recurrence of breast cancer in postmenopausal…
- Trial name
- WISE (NCT00090857)
- Testing
- Letrozole
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphedema
Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection
This randomized phase III trial studies how well education with or without physical therapy intervention works in preventing lymphedema in women with stage I, II, or III breast cancer who are undergoing axillary lymph node…
- Trial name
- NCT00376597
- Testing
- quality of life assessment, educational intervention, Physical therapy
- Where
- 76 sites in United States
- Sponsor
- Alliance for Clinical Trials in Oncology
Melanoma, Renal Cell Carcinoma
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D.
- Conditions
- Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- PIVOT-02 (NCT02983045)
- Testing
- Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
- Where
- 58 sites in United States, Belgium and 6 more
- Volunteers
- 557 people
- Sponsor
- Nektar Therapeutics
Breast Cancer
Breast Cancer Risk Biomarkers in Premenopausal Women
This study is designed to gather information on how the prescription drug Lovaza™ which contains omega-3 fatty acids, affects blood and tissue risk biomarkers for breast cancer.
- Trial name
- NCT01252277
- Testing
- Lovaza™
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Carol Fabian, MD
Breast Cancer
ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial
The primary objective is to assess the event-free survival defined as the time from randomisation to progression, death without progression, loss to follow up, whichever occurred first..
- Trial name
- ZACFAST (NCT00752986)
- Testing
- ZD6474 (Vandetanib at the dose of 100 mg), Fulvestrant, ZD6474 (Vandetanib at the dose of 300 mg)
- Where
- 11 sites in Italy
- Volunteers
- 39 people
- Sponsor
- Genzyme, a Sanofi Company
Early-stage Breast Cancer, Breast Cancer Female
The ConnectedCancerCare Pilot Study (CCC)
This study is an NCI-funded, randomized control pilot trial to evaluate: (1) the feasibility and acceptability of a web-based, personalized navigation tool (ConnectedCancerCare) and (2) explore whether the tool improves delivery…
- Conditions
- Early-stage Breast Cancer, Breast Cancer Female, Survivorship, Cancer Survivors
- Trial name
- CCC (NCT03618017)
- Testing
- CCC website, Static care plan
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Michigan Rogel Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer
This is a single center phase II trial designed to optimize a clinical platform of lymphodepleting chemotherapy and T-cell suppression to promote the persistence, function, and expansion of allogeneic natural killer (NK) cells in…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Breast Cancer
- Trial name
- NCT01105650
- Testing
- Fludarabine, Cyclophosphamide, Cyclosporine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Atrophic Vaginitis, Breast Cancer
Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen
The purpose of this study is to see if Vagifem® 10mcg is safe for women who have had breast cancer. Vagifem is an estrogen product. It is a tiny tablet that is inserted into the vagina. It relieves vaginal dryness.
- Trial name
- NCT00984399
- Testing
- Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist
- Where
- 5 sites in United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
RATIONALE: Dose-dense scheduling with (peg)filgrastim support may improve the clinical and pathologic complete response rate (pCR) and safety profile of single agent neoadjuvant docetaxel therapy.
- Trial name
- NCT00343512
- Testing
- docetaxel, protein expression analysis, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer, Psychology, Social
Effectiveness of Screening and Brief Interventions for Alcohol and Tobacco During Breast Cancer Treatment (ONKODETOX)
Despite scientific, clinical and political incentives, alcohol and/or tobacco screening and brief intervention (SBI) services are poorly implemented in oncology settings.
- Trial name
- ONKODETOX (NCT03371732)
- Testing
- Motivational Intervention group, Educational advises group
- Where
- France
- Volunteers
- 104 people
- Sponsor
- Institut Bergonié
Recurrent Breast Cancer, Stage IIIB Breast Cancer
Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer
This phase I/II trial studies the best dose of suramin when given together with paclitaxel in treating women with stage IIIB-IV breast cancer.
- Conditions
- Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT00054028
- Testing
- suramin, paclitaxel, pharmacological study
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases
RATIONALE: Surgery to remove lymph nodes in the armpit in patients with sentinel lymph node micrometastases may remove cancer cells that have spread from tumors in the breast.
- Trial name
- 23-01 (NCT00072293)
- Testing
- Axillary lymph node dissection, No axillary lymph node dissection
- Where
- 31 sites in Australia, Belgium and 8 more
- Volunteers
- 931 people
- Sponsor
- ETOP IBCSG Partners Foundation
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery
This phase II trial is studying how well giving entinostat and anastrozole together works in treating postmenopausal women with triple-negative breast cancer that can be removed by surgery.
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage I Breast Cancer
- Trial name
- 0927GCC (NCT01234532)
- Testing
- entinostat, anastrozole, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Maryland, Baltimore
Neoplasms, Breast
Treatment With Pazopanib for Neoadjuvant Breast Cancer
The purpose of this study is to determine whether the treatment of a doxorubicin in combination with cyclophosphamide followed by a combination of pazopanib in combination with paclitaxel prior to surgery results in a…
- Trial name
- NCT00849472
- Testing
- doxorubicin + cyclophosphamide, paclitaxel + pazopanib, surgery
- Where
- 143 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- GlaxoSmithKline
Solid Tumor
A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
This was a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that had select mutations or alterations in human epidermal growth factor receptor 2 (HER2/ErbB2) genes or epidermal…
- Trial name
- MasterKey-01 (NCT04209465)
- Testing
- BDTX-189
- Where
- 38 sites in United States, Denmark and 2 more
- Volunteers
- 91 people
- Sponsor
- Black Diamond Therapeutics, Inc.
Breast Cancer
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00616967
- Testing
- carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, vorinostat
- Where
- 5 sites in United States
- Volunteers
- 68 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer
Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer
The majority pf breast cancers present as ER-positive, many of which are able to be targeted with multiple hormonal therapies. Altering ER-negative tumors to increase ER expression has the potential to benefit patients by making…
- Trial name
- NCT00726180
- Testing
- trastuzumab (Herceptin®)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Michigan Rogel Cancer Center
Her2 Negative Breast Cancer Patients
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer
To determine whether the combination MM-121 + Exemestane in ER+ and/or PR+ breast cancer patients is more effective than Exemestane alone
- Trial name
- NCT01151046
- Testing
- MM-121, Exemestane
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 118 people
- Sponsor
- Merrimack Pharmaceuticals
Breast Neoplasm Female
Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis.
- Trial name
- NCT03096418
- Testing
- Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Wisconsin, Madison